• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Comparing survival of responders and nonresponders after treatment: a potential source of confusion in interpreting cancer clinical trials.

作者信息

Weiss G B, Bunce H, Hokanson J A

出版信息

Control Clin Trials. 1983 Mar;4(1):43-52. doi: 10.1016/s0197-2456(83)80011-7.

DOI:10.1016/s0197-2456(83)80011-7
PMID:6851582
Abstract

The comparison of survival distributions between patients who respond to therapy and those who do not can present methodologic and interpretational difficulties. Since assignment of patients to the responder or nonresponder groups is not random, statistical procedures that test the equality of survival distributions only demonstrate association between response and survival, not cause and effect. This association may have no relevance to the efficacy of treatment. The assignment of patients to response categories also represents a methodologic problem. Variability in the definition of a nonresponder and the handling of early deaths can both lead to varying conclusions concerning survival. In spite of these problems, statistical comparisons of survival distributions of responders and nonresponders are reported in approximately 20% of phase II and phase III clinical trials. Descriptive statistics may be more useful than inferential statistics in this situation.

摘要

相似文献

1
Comparing survival of responders and nonresponders after treatment: a potential source of confusion in interpreting cancer clinical trials.
Control Clin Trials. 1983 Mar;4(1):43-52. doi: 10.1016/s0197-2456(83)80011-7.
2
Historical and methodological developments in clinical trials at the National Cancer Institute.美国国立癌症研究所临床试验的历史与方法学发展
Stat Med. 1990 Aug;9(8):871-80; discussion 903-6. doi: 10.1002/sim.4780090803.
3
Impact of multiple comparisons in randomized clinical trials.随机临床试验中多重比较的影响。
Am J Med. 1987 Sep;83(3):545-50. doi: 10.1016/0002-9343(87)90768-6.
4
Reporting results from chemotherapy trials. Does response make a difference in patient survival?
JAMA. 1984 Nov 16;252(19):2722-5.
5
The impact that group sequential tests would have made on ECOG clinical trials.
Stat Med. 1989 Apr;8(4):505-16. doi: 10.1002/sim.4780080413.
6
Evaluation of toxicity: statistical considerations.毒性评估:统计学考量
Cancer Treat Rep. 1980 Feb-Mar;64(2-3):463-8.
7
Testing for a treatment effect in the presence of nonresponders.
Biometrics. 1986 Mar;42(1):191-7.
8
Designs for experiments--parallel comparisons of treatment.
N Engl J Med. 1983 Nov 24;309(21):1291-9. doi: 10.1056/NEJM198311243092105.
9
Illusion and reality: practical pitfalls in interpreting clinical trials.幻想与现实:解读临床试验中的实际陷阱
J Clin Oncol. 1984 May;2(5):488-97. doi: 10.1200/JCO.1984.2.5.488.
10
A design for phase II testing of anticancer agents within a phase III clinical trial.一种在III期临床试验中进行抗癌药物II期测试的设计。
Control Clin Trials. 1988 Jun;9(2):107-18. doi: 10.1016/0197-2456(88)90032-3.

引用本文的文献

1
Objective Response to Systemic Therapy Is a Strong Predictor of Overall Survival in Patients with Unresectable Hepatocellular Carcinoma.全身治疗的客观反应是不可切除肝细胞癌患者总生存的有力预测指标。
Liver Cancer. 2023 Nov 29;13(1):1-5. doi: 10.1159/000535516. eCollection 2024 Feb.
2
Effect of onset of type 2 diabetes on risks of cardiovascular disease and heart failure among new Zealanders with impaired glucose tolerance over 25 years: tapered-matched landmark analysis.25 年内新西兰糖耐量受损人群中 2 型糖尿病发病对心血管疾病和心力衰竭风险的影响:缩尾匹配标志分析。
Cardiovasc Diabetol. 2023 Jun 30;22(1):163. doi: 10.1186/s12933-023-01871-y.
3
Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.
ECOG 4599 研究中卡铂和紫杉醇联合贝伐珠单抗治疗的晚期非小细胞肺癌患者发生高血压的临床过程。
J Clin Oncol. 2010 Feb 20;28(6):949-54. doi: 10.1200/JCO.2009.25.4482. Epub 2010 Jan 19.
4
Endpoints in phase II trials for advanced non-small cell lung cancer.Ⅱ期临床试验中晚期非小细胞肺癌的终点。
J Thorac Oncol. 2010 Jan;5(1):3-9. doi: 10.1097/JTO.0b013e3181c0a313.
5
Benefits and limitations of Kaplan-Meier calculations of survival chance in cancer surgery.癌症手术中生存机会的Kaplan-Meier计算法的益处与局限性
Langenbecks Arch Surg. 2003 Sep;388(4):239-44. doi: 10.1007/s00423-003-0410-6. Epub 2003 Aug 14.
6
Estimation of prolongation of hospital stay attributable to nosocomial infections: new approaches based on multistate models.医院感染所致住院时间延长的估计:基于多状态模型的新方法
Lifetime Data Anal. 1996;2(3):219-40. doi: 10.1007/BF00128975.
7
Meningeal carcinomatosis from breast cancer: spinal cord vs. brain involvement.乳腺癌脑膜癌病:脊髓与脑受累情况
Breast Cancer Res Treat. 1987;9(3):213-7. doi: 10.1007/BF01806382.
8
Response to cytostatic treatment in inoperable adenocarcinoma of the lung: critical implications.不可切除的肺腺癌对细胞抑制治疗的反应:关键意义
Br J Cancer. 1989 Sep;60(3):389-93. doi: 10.1038/bjc.1989.291.